BioCentury | Mar 30, 2018
Clinical News

Edge discontinues sole clinical candidate EG-1962

...Edge Therapeutics Inc. (NASDAQ:EDGE) said it will discontinue development of EG-1962 after an IDMC said the...
...on a prespecified interim analysis by the IDMC of the first 210 patients that showed EG-1962...
...drain. The company also discontinued a Phase I trial evaluating intracisternal EG-1962 to treat aSAH. EG-1962...
BioCentury | Mar 28, 2018
Clinical News

Edge falls after discontinuing sole clinical candidate

...$14.28 (92%) to $1.31 on Wednesday when the company said it will discontinue development of EG-1962...
...SOC for up to 21 days or a single 600 mg intraventricular injection of EG-1962. EG-1962...
...drain. The company also discontinued a Phase I trial evaluating intracisternal EG-1962 to treat aSAH. EG-1962...
BioCentury | Aug 8, 2016
Clinical News

EG-1962: Phase III started

...U.S. Phase III NEWTON 2 trial to compare a single intraventricular injection of 600 mg EG-1962...
...aSAH) resulting from a ruptured brain aneurysm. Edge Therapeutics Inc. (NASDAQ:EDGE), Berkeley Heights, N.J. Product: EG-1962...
BioCentury | Feb 22, 2016
Clinical News

EG-1962: Additional Phase I/II data

...that the median intensive care unit length of stay for a single intraventricular infusion of EG-1962...
...4 hours for 21 days. The median length of hospital stay was 22.5 days for EG-1962...
...vs. 25 days for SOC. Patients received 100, 200, 400, 600, 800 or 1,200 mg EG-1962...
BioCentury | Oct 2, 2015
Financial News

Edge, Mirna price IPOs

...Guggenheim; and JMP Securities. Next year, Edge expects to begin a Phase III trial of EG-1962...
...The compound has Orphan Drug designation from FDA to prevent delayed cerebral ischemia after aSAH. EG-1962...
BioCentury | Sep 7, 2015
Clinical News

EG-1962: Phase I/II data

...of 800 mg was the maximum tolerated dose (MTD) of EG-1962. No patients that received EG-1962...
...standard of care -- 60 mg oral nimodipine given every 4 hours for 21 days. EG-1962...
...800 or 1,200 mg EG-1962 or nimodipine. Edge Therapeutics Inc. , Berkeley Heights, N.J. Product: EG-1962...
BioCentury | Jun 8, 2015
Clinical News

EG-1962: Completed Phase I/II enrollment

...trial comparing a single dose of 100, 200, 400, 600, 800 and 1,200 mg intraventricular EG-1962...
...given every 4 hours for 21 days. Edge Therapeutics Inc. , Berkeley Heights, N.J. Product: EG-1962...
BioCentury | Apr 10, 2015
Financial News

Edge raises $72.5M in additional series C rounds

...2013) . Edge expects topline data in mid-2015 from the Phase I/II NEWTON trial of EG-1962...
...reported interim data showing that 61% of patients who received a single intraventricular dose of EG-1962...
BioCentury | Feb 16, 2015
Clinical News

EG-1962: Interim Phase I/II data

...international Phase I/II NEWTON trial showed that single doses of 100 and 200 mg intraventricular EG-1962...
...the validated 8-point scale. Additionally, there was no evidence of hypotension in patients treated with EG-1962...
...receive an 800 mg dose of EG-1962. Edge Therapeutics Inc. , New Providence, N.J. Product: EG-1962...
BioCentury | Nov 11, 2013
Clinical News

EG-1962: Phase I/II started

...the open-label, dose-escalation, international Phase I/II NEWTON trial to compare a single dose of intraventricular EG-1962...
...patients who had a subarachnoid hemorrhage (SAH). Edge Therapeutics Inc. , New Providence, N.J. Product: EG-1962...
Items per page:
1 - 10 of 12